Windlas Biotech Limited has announced a board meeting to review the financial results for the quarter and half-year.

The company reports strong operational progress with enhanced manufacturing capabilities and expanded contract manufacturing orders, supporting revenue growth.

Ongoing investments in R&D and capacity expansion aim to sustain product pipeline development.

Debt levels remain manageable with improving cash flows.

Overall, the company is positioned for steady growth amid increasing market demand for its pharmaceutical formulations and vaccine segments.